DK1341528T3 - Hurtigtopløsende tablet omfattende en syrelabil aktiv bestanddel - Google Patents

Hurtigtopløsende tablet omfattende en syrelabil aktiv bestanddel

Info

Publication number
DK1341528T3
DK1341528T3 DK01999360.9T DK01999360T DK1341528T3 DK 1341528 T3 DK1341528 T3 DK 1341528T3 DK 01999360 T DK01999360 T DK 01999360T DK 1341528 T3 DK1341528 T3 DK 1341528T3
Authority
DK
Denmark
Prior art keywords
active ingredient
acid
tablet
acidable
quick
Prior art date
Application number
DK01999360.9T
Other languages
Danish (da)
English (en)
Inventor
Rango Dietrich
Rudolf Linder
Hartmut Ney
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Application granted granted Critical
Publication of DK1341528T3 publication Critical patent/DK1341528T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
DK01999360.9T 2000-12-07 2001-12-06 Hurtigtopløsende tablet omfattende en syrelabil aktiv bestanddel DK1341528T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00126807 2000-12-07
PCT/EP2001/014340 WO2002045694A1 (en) 2000-12-07 2001-12-06 Rapidly disintegrating tablet comprising an acid-labile active ingredient

Publications (1)

Publication Number Publication Date
DK1341528T3 true DK1341528T3 (da) 2012-03-26

Family

ID=8170591

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01999360.9T DK1341528T3 (da) 2000-12-07 2001-12-06 Hurtigtopløsende tablet omfattende en syrelabil aktiv bestanddel

Country Status (15)

Country Link
US (1) US7147869B2 (cg-RX-API-DMAC7.html)
EP (1) EP1341528B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004514737A (cg-RX-API-DMAC7.html)
KR (1) KR20030072555A (cg-RX-API-DMAC7.html)
CN (1) CN100335040C (cg-RX-API-DMAC7.html)
AT (1) ATE541564T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002221939A1 (cg-RX-API-DMAC7.html)
BR (1) BR0115986A (cg-RX-API-DMAC7.html)
CA (1) CA2430829C (cg-RX-API-DMAC7.html)
CY (1) CY1112615T1 (cg-RX-API-DMAC7.html)
DK (1) DK1341528T3 (cg-RX-API-DMAC7.html)
ES (1) ES2380654T3 (cg-RX-API-DMAC7.html)
PT (1) PT1341528E (cg-RX-API-DMAC7.html)
SI (1) SI1341528T1 (cg-RX-API-DMAC7.html)
WO (1) WO2002045694A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
JP5009482B2 (ja) * 2000-12-07 2012-08-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸に不安定な活性成分を含有する懸濁液の形の製薬製剤
SI1341524T1 (sl) * 2000-12-07 2012-02-29 Nycomed Gmbh Farmacevtski pripravek v obliki paste, ki obsega kislinsko labilno učinkovino
EP1416922A1 (en) * 2001-07-16 2004-05-12 AstraZeneca AB Pharmaceutical formulation comprising a proton pump inhibitor and antacids
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
EA009985B1 (ru) 2003-03-10 2008-04-28 Никомед Гмбх Новый способ получения рофлумиласта
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US8057820B2 (en) * 2004-10-08 2011-11-15 Mcneil-Ppc, Inc. Enteric coated aspirin granules comingled with binder
US8758814B2 (en) * 2004-10-08 2014-06-24 Mcneil-Ppc, Inc. Chewable enteric coated aspirin tablets
ES2421916T3 (es) 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
FR2885526B1 (fr) * 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
CN100431526C (zh) * 2005-11-07 2008-11-12 上海艾力斯医药科技有限公司 一种酸敏感型药物的快速崩解片剂
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
DE202006020168U1 (de) * 2005-12-21 2008-07-17 Basf Se Pharmazeutische Formulierung für die Herstellung von schnell zerfallenden Tabletten
EP2164460B1 (de) * 2007-06-06 2017-08-09 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
EP2164462B1 (de) * 2007-06-06 2017-05-31 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
RU2010119041A (ru) * 2007-10-12 2011-11-20 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи
DE102010011421A1 (de) * 2009-03-19 2010-09-30 Schaeffler Technologies Gmbh & Co. Kg Schaltbarer Schlepphebel eines Ventiltriebs einer Brennkraftmaschine
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
EP2544665A4 (en) * 2010-03-11 2014-01-01 Rich Vitamins Llc NUTRITIONAL POWDER WITH RAPID DISSOLUTION
EP2583673A1 (en) * 2010-10-14 2013-04-24 Deva Holding Anonim Sirketi Coating of cetyl myristate and/or cetyl palmitate particles
EP2441446A1 (en) * 2010-10-14 2012-04-18 Deva Holding Anonim Sirketi Using of superdisintegrants in cetyl myristate and/or cetyl palmitate formulations
JP5913367B2 (ja) 2011-01-05 2016-04-27 ホスピーラ インコーポレイテッド バンコマイシンの噴霧乾燥
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN120585773B (zh) * 2025-08-06 2025-11-07 广州仁恒医药科技股份有限公司 一种盐酸米诺环素胶囊及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065142A (en) * 1958-07-30 1962-11-20 Armour Pharma Gastric resistant medicinal preparation
US4006227A (en) * 1973-11-15 1977-02-01 Gallegos Alfred J Compositions and methods for fertility control
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US5380535A (en) * 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
ES2202302T3 (es) * 1991-05-28 2004-04-01 Mcneil-Ppc, Inc. Composicion masticable que libera un farmaco.
TW391880B (en) * 1994-01-31 2000-06-01 Yamanouchi Pharma Co Ltd An oral soluble type compression moulding and its preparation
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
DK1078628T3 (da) 1994-07-08 2009-02-23 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
SE512835C2 (sv) 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
JP4939680B2 (ja) * 1997-05-27 2012-05-30 武田薬品工業株式会社 固形製剤
JP2001526212A (ja) * 1997-12-19 2001-12-18 スミスクライン・ビーチャム・コーポレイション 咀嚼分散性錠剤の製造法
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
PT1121103E (pt) * 1998-05-18 2007-02-28 Takeda Pharmaceutical Comprimidos de desintegração oral compreendendo um benzimidazole
ES2237121T3 (es) * 1998-07-28 2005-07-16 Takeda Pharmaceutical Company Limited Preparacion solida disgregable rapidamente.
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
DE19925710C2 (de) * 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
EE200100660A (et) * 1999-06-07 2003-04-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Ravimvorm happe suhtes labiilsete toimeainete jaoks, toimeaine üksus, selle valmistamismeetod ja mikrokerake

Also Published As

Publication number Publication date
PT1341528E (pt) 2012-03-20
CY1112615T1 (el) 2016-02-10
CN1479613A (zh) 2004-03-03
ES2380654T3 (es) 2012-05-17
CA2430829A1 (en) 2002-06-13
HK1062264A1 (zh) 2004-10-29
SI1341528T1 (sl) 2012-05-31
CA2430829C (en) 2010-06-22
US20040110661A1 (en) 2004-06-10
EP1341528A1 (en) 2003-09-10
ATE541564T1 (de) 2012-02-15
WO2002045694A1 (en) 2002-06-13
CN100335040C (zh) 2007-09-05
KR20030072555A (ko) 2003-09-15
US7147869B2 (en) 2006-12-12
AU2002221939A1 (en) 2002-06-18
EP1341528B1 (en) 2012-01-18
BR0115986A (pt) 2003-12-23
JP2004514737A (ja) 2004-05-20

Similar Documents

Publication Publication Date Title
SI1341528T1 (sl) Hitro razpadljiva tableta ki obsega kislinsko labilno aktivno sestavino
NO20032593D0 (no) Farmasöytisk fremstilling omfattende en aktiv bestanddel dispergert på en matrise
AP2397A (en) Matrix for sustained, invariant and independent release of active compounds.
HUP0201637A2 (hu) Savval szemben labilis vegyületet tartalmazó új készítmény és adagolási forma
ATE334689T1 (de) Verabreichungsmedium für analgetische, entzündungshemmende und antipyretische wirkstoffe und pharmazeutische zusammensetzungen enthaltend solches medium und wirkstoffe
AR032073A1 (es) Las nanoparticulas lipidas anfifilicas para la incorporacion de los peptidos y/o las proteinas
ATE226815T1 (de) Herstellung von arzneimitteln
ES2079485T3 (es) Composiciones farmaceuticas y un dispositivo para administrar las mismas.
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
DK1341524T3 (da) Farmaceutisk præparat i form af en pasta omfattende en syre-labil aktiv bestanddel
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
SE9704401D0 (sv) Matrix pellets for greasy, oily or sticky drug substances
HRP20010684B1 (hr) Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
GEP20053455B (en) Pharmaceutical Preparations
YU17899A (sh) Farmaceutske mikrosfere valproinske kiseline za oralnu upotrebu
MY138975A (en) Novel preparation and administration form comprising an acid-labile active compound
DK0584126T3 (da) Lanolinderivater som penetrationsfremmende stoffer
WO2020224649A1 (zh) 含光皮树提取物的制剂及其应用
AR043370A1 (es) Composiciones farmaceuticas de administracion oral y metodos para evitar la interaccion alimento -droga
ES2193514T3 (es) Utilizacion de combinaciones de sustancias activas a base de antibioticos y de estractos vegetales que contienen terpenos en la medicina veterinaria.
Mohmed et al. Efficacy of Aloe vera in Treatment of Experimentally Induced Oral Lichenoid Reaction
ECSP024290A (es) Composiciones farmacéuticas y uso de las mismas
UA77246C2 (en) Pharmaceutical composition containing pancreatin and dry extract from herb of pea
MY142110A (en) Matrix for sustained, invariant and independent release of active compounds